

Living Research



Currently enrolling studies at The Neurological Institute, Research Department

Winter 2011

NEW!

Multiple Sclerosis A study to evaluate the safety and efficacy of oral Dalfampridine Extended Release tablets in MS patients

- 18-70 years old
- Diagnosed with MS
- Must be able to complete a 25 foot walking test

NEW!

Multiple Sclerosis A study to evaluate patient outcomes, safety and tolerability of Fingolimod FTY720 with RRMS patients who are candidates for MS therapy change.

- 18 – 65 years old
- Must be receiving continuous treatment with an approved DMT for MS for 6 months prior
- Naïve to treatment with Fingolimod FTY720

NEW!

Multiple Sclerosis A study of the efficacy and safety of Teriflunomide in RRMS patients who are treated with interferon-beta

- 18 – 55 years old
- Must be currently treated with interferon-beta (INF- β)

Multiple Sclerosis A study to evaluate the efficacy and safety of two year treatment with teriflunomide in patients with a first clinical episode suggestive of MS

- 18-55 years old
- 1st onset of MS symptoms, occurring within 30 days, such as optic neuritis, spinal cord syndrome, brainstem/celebellar syndromes

Multiple Sclerosis A study of the safety and efficacy of ONO-4641 in patients with Relapsing Remitting MS

- 18-55 years old
- Diagnosis of RRMS
- <10 lesions on MRI
- Patient must have had 1st MS symptom experience <12 years

Multiple Sclerosis A study to evaluate the benefits of switching therapy from Copaxone or Rebif to Tysabri in subjects with Relapsing Remitting MS

- 18-60 years old
- Naïve to Tysabri
- Diagnosis of RRMS
- Treated with a stable regimen of either Copaxone or Rebif for 6 to 18 months

Multiple Sclerosis JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or considering Treatment with Tysabri®

Insomnia A Study to Evaluate the Safety and Efficacy of Patients with Primary Insomnia

- \geq 18 year
- Diagnosis of Primary Insomnia

Neuropathic Pain A study to Evaluate the Efficacy, Safety and Tolerability of study medications in Patients with Postherpetic Neuralgia and Post-Traumatic Neuralgia, Followed by a Safety Extension and an Open-Label Safety Extension.

- 18 – 80 years old
- Have chronic neuropathic pain and are currently taking neuropathic pain medication that are not adequately controlled
- Diagnosis of Postherpetic Neuralgia (PHN)
- Diagnosis of Post-Traumatic Neuralgia

Parkinson's Disease A study to evaluate the efficacy and safety of pramipexole in subjects with moderate to severe Parkinson's

- \geq 30 to \leq 85 years of age
- Diagnosis of idiopathic PD
- Must be on a stable dose of L-dopa for approximately 2 or more years

Parkinson's Disease A study to evaluate the efficacy and safety of pramipexole in subject with early Parkinson's

- \geq 30 to \leq 85 years of age
- Diagnosis of idiopathic PD
- Can't be on L-dopa or dopamine agonist

Parkinson's Disease A study to determine the efficacy and safety of a dose range of 50 to 100mg/daily of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations treated with a stable dose of levodopa (Sinemet)

- 30-80 years old
- Diagnosis of idiopathic PD of more than 5 years
- On stable dose of levodopa 4 weeks prior

Parkinson's Disease A study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic PD, treated with dopamine agonist

- 30-80 years old
- Diagnosis of idiopathic PD less than 5 years
- On stable dose of dopamine agonist 4 weeks prior

Epilepsy An efficacy and safety study of Eslicarbazepine Acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures

- 16 years or older
- Diagnosis of epilepsy for 12 months
- Currently treated with 1 or 2 AED's and in a stable dose regimen 1 month prior
- At least 4 partial-onset seizures on the 4 weeks prior to screening (includes subtype of simple partial, complex partial and partial seizures evolving to secondarily generalized)

Questions can be submitted to the Research Department by email: research@neuro-institute.com

Research Department Contacts: Myrna Shrum 704-335-6483 • Marguerite Buckley 704-331-7856 • Manisha Yadav 704-342-6014

2607 East 7th Street, Suite 200, Charlotte, NC 28204 • www.neuro-institute.com